Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
AssigneeSensco Technologies, Inc.
InventorsCatherine Taylor, Dominic Cliche, Elizabeth Margaret Heikkila, Diane Michelle Senchyna, John Gerard Flanagan, John E. Thompson
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIfF5A1.
Claims11
1) A method for preventing retinal ganglion cell death in a glaucomatous eye, said method comprising suppressing expression of apoptosis-specific eIF5A1 in retinal ganglion cells.
6) A method of suppressing expression of apoptosis-specific eIF5A1 in lamina cribosa cells, the method comprising transfecting lamina cribosa cells with antisense oligonucleotides targeted against human apoptosis-specific eIF5A1, wherein said antisense oligonucleotides supress expression of apoptosis-specific eIF5A1 in said cells.
10) A method of suppressing expression of apoptosis-specific eIF5A1 in astrocyte cells, the method comprising transfecting astrocyte cells with antisense oligonucleotides targeted against human apoptosis-specific eIF5A1, wherein said antisense oligonucleotides supress expression of apoptosis-specific eIF5A1 in said cells.
Dependencies are inferred from the claim text.